Study of the Effect of Innate on the Inflammatory Response to Endotoxin
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNational Institute of Environmental Health Sciences (NIEHS)
About this trial
Background:
\- Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers.
Objectives:
\- To examine how specific genes and proteins in blood cells respond to environmental exposures.
Eligibility:
\- Healthy volunteers between 18 and 45 years of age.
Design:
* The study will involve one visit of 45 to 60 minutes. * Participants will be screened with a brief physical examination and finger stick to determine if they are eligible to donate blood for the study, and will complete a questionnaire about any medications or other drugs (e.g., cigarettes) they may be taking. * Participants will provide a blood sample for research purposes.
Eligibility criteria
Qualifiers
Male or female 18 years of age or older
Participants must be able to understand and provide written informed consent to participate in the study
Participants must be able to travel to the CRU
Willing and able to fast after midnight the night prior to their study appointment.
Disqualifiers
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) within 5 days prior to enrollment visit (e.g., Motrin, ibuprofen, naproxen, and Advil)
Use of acetaminophen (Tylenol) within 5 days prior to enrollment visit
Use of cholesterol lowering drugs (statins) within 30 days prior to enrollment visit (e.g., Zocor, Mevacor, Lipitor, and Crestor)
Use of immunosuppressants or other immune-modifying drugs [e.g., Rituxan, Humira, Enbrel, Cyclosporin (Neoral, Sandimmune, and SangCya), and Azathioprine (Imuran)], Monoclonal antibodies [e.g., infliximab (Remicade)], and corticosteroids (e.g., prednisone, prednisolone and dexamethasone)
Trial design
Treatments tested in this trial
- Not listed
Trial groups
725 Participants
are grouped into 13 trial groups13
Trial groupsSee each trial group below.
Sponsors and collaborators
Source ClinicalTrials.gov